Molecular Detection Inc.

Molecular Detection Inc. (MDI) operates in the healthcare sector, specifically focusing on the development and commercialization of molecular diagnostic tests for infectious diseases. The company provides "sample-to-answer" Detect-Ready™ diagnostic solutions designed to enhance the speed and precision of disease detection. Its primary clients are hospitals and other healthcare facilities grappling with the challenge of healthcare-associated infections.

The company's business centers on providing qualitative real-time PCR (rt-PCR) in vitro diagnostic tests. A key product is the Detect-Ready™ MRSA kit, a screening assay for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) from nasal swabs. This addresses the significant issue of MRSA, a drug-resistant staph infection that poses a serious threat to patient safety and increases healthcare costs. The technology aims to minimize the false positives and negatives that can be an issue with other screening kits, thereby providing more accurate results. By delivering faster and more precise diagnoses, MDI's products enable healthcare providers to implement timely infection control measures, which can prevent the spread of disease within their facilities.

The company's financial history includes a Series C funding round of $3.3 million in late 2009, followed by a $1.4 million follow-on financing in June 2010. This funding, led by existing investors like MentorTech Ventures II, LP, was intended to support new product development and provide working capital for business expansion. At the time of this financing, Todd Wallach served as the chairman and CEO. MDI had established a commercial presence with its MRSA assay in several European markets, including the UK, Germany, Ireland, Switzerland, and Austria, and was planning further expansion.

Keywords: molecular diagnostics, infectious disease testing, real-time PCR, in vitro diagnostic, MRSA screening, healthcare-associated infections, diagnostic assays, pathogen detection, medical diagnostics, antimicrobial resistance, hospital infection control, Detect-Ready, rt-PCR tests, differential diagnosis, molecular detection, medical technology, life sciences, diagnostic commercialization